Cargando…

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

Detalles Bibliográficos
Autores principales:	Sponghini, Andrea P, Rondonotti, David, Giavarra, Marco, Giorgione, Roberto, Platini, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315287/ http://dx.doi.org/10.1186/1479-5876-13-S1-P7

Ejemplares similares

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)
por: Clark, Joseph, et al.
Publicado: (2014)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
por: Nowara, Elzbieta, et al.
Publicado: (2016)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)
por: Ascierto, Paolo A, et al.
Publicado: (2015)

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation–positive melanoma
por: Dréno, Brigitte, et al.
Publicado: (2018)

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
por: Chapman, P B, et al.
Publicado: (2017)

Vemurafenib in Chinese patients with BRAF(V600) mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
por: Si, Lu, et al.
Publicado: (2018)

BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
por: Giovannoni, Sara, et al.
Publicado: (2015)

Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
por: Sahadudheen, K., et al.
Publicado: (2016)

Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
por: Cai, Chao, et al.
Publicado: (2021)

The clinical response to vemurafenib in a patient with a rare BRAF(V600DK601del) mutation-positive melanoma
por: Trudel, Stéphanie, et al.
Publicado: (2014)

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
por: Shelledy, Lindsay, et al.
Publicado: (2015)

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
por: Sapkota, Bishu, et al.
Publicado: (2013)

Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma
por: Sarnaik, Amod, et al.
Publicado: (2015)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
por: Clark, Joseph I., et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
por: Gao, Tianfu, et al.
Publicado: (2021)

Preclinical Evaluation of Vemurafenib as Therapy for BRAF(V600E) Mutated Sarcomas
por: Gouravan, Sarina, et al.
Publicado: (2018)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF(V600E)-Specific Inhibitor)
por: Torres-Collado, Antoni Xavier, et al.
Publicado: (2018)

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma
por: Yan, Yibing, et al.
Publicado: (2014)

The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study
por: Knapen, Lotte M., et al.
Publicado: (2018)

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
por: Álamo, Mª del Carmen, et al.
Publicado: (2021)

The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
por: Porcelli, Letizia, et al.
Publicado: (2015)

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF(V600) Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
por: Ascierto, Paolo A., et al.
Publicado: (2021)

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7)
por: Puzanov, Igor, et al.
Publicado: (2014)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
por: Amin, Asim, et al.
Publicado: (2016)

Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF(V600) melanoma cells
por: Smith, Lorey K., et al.
Publicado: (2020)

Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf(V600E) Melanoma
por: Signetti, Laurie, et al.
Publicado: (2020)

EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF(V600E) Mutated Parent- and Vemurafenib-Resistant Melanoma
por: Fu, Yige, et al.
Publicado: (2019)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial
por: Rutkowski, Piotr, et al.
Publicado: (2015)

HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF(V600E) Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia
por: Furfaro, Anna Lisa, et al.
Publicado: (2022)

Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study
por: Zakharia, Yousef, et al.
Publicado: (2017)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
por: Moiseyenko, Fedor V., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gqcsph7hgq0jg1g3edasfbtgko